Two specific types, HPV 16 and HPV18, account for 70 percent of these cases.1,2
In ATHENA, the largest-ever study of cervical cancer screening practices, more than 47,000 women were tested for high-risk HPV types using the cobas® HPV Test. The study proved that HPV screening was more effective than Pap tests in both detecting and predicting high-grade cervical disease.
Roche is committed to helping change the standard of HPV screening to give women everywhere the best chance to prevent cervical cancer.
New Professional Guidelines Recognize Benefit of Genotyping HPV 16 and 18 for Cervical Cancer Prevention by Assessing Individual Patient Risk
Pleasanton, California, March 15, 2012
Evidence to support DNA genotyping for HPV as a co-testing approach provided by Roche’s landmark ATHENA study
